Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Receivables (2016 - 2025)

Abeona Therapeutics has reported Receivables over the past 14 years, most recently at $500003.0 for Q4 2025.

  • Quarterly results put Receivables at $500003.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $500003.0 (changed N/A YoY), and the annual figure for FY2025 was $500003.0, changed.
  • Receivables for Q4 2025 was $500003.0 at Abeona Therapeutics, down from $5.6 million in the prior quarter.
  • Over the last five years, Receivables for ABEO hit a ceiling of $27.3 million in Q3 2022 and a floor of $500003.0 in Q4 2025.
  • Median Receivables over the past 4 years was $6.0 million (2021), compared with a mean of $13.3 million.
  • Peak annual rise in Receivables hit 79.49% in 2023, while the deepest fall reached 79.49% in 2023.
  • Abeona Therapeutics' Receivables stood at $6.0 million in 2021, then soared by 355.78% to $27.3 million in 2022, then tumbled by 79.52% to $5.6 million in 2023, then tumbled by 91.07% to $500003.0 in 2025.
  • The last three reported values for Receivables were $500003.0 (Q4 2025), $5.6 million (Q2 2023), and $27.3 million (Q3 2022) per Business Quant data.